医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

The SCIEX 7500+ System Launches at ASMS 2024

2024年06月04日 AM03:00
このエントリーをはてなブックマークに追加


 

FRAMINGHAM, Mass.

At ASMS 2024, SCIEX, a global leader in life science analytical technologies, launches the SCIEX 7500+ system, the newest mass spectrometer in the SCIEX quantitative portfolio, building upon a legacy of reliable, sensitive quantitation. While sensitivity is critical to solve the most impactful analytical challenges, scientists are under pressure to meet deadlines faster and to quantify from increasingly various and complex sample types. The SCIEX 7500+ system delivers both sensitivity and resilience when scientists need it most.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240603002122/en/

The SCIEX 7500+ system (Photo: Business Wire)

The SCIEX 7500+ system (Photo: Business Wire)

The SCIEX 7500+ system offers increased resilience across a large suite of sample types and workflows, and improved user-serviceability.

     

Mass Guard technology is a new proprietary technology that includes the ability to actively filters out potentially contaminating ions. It reduces the risk and frequency of instrument contamination, helping to maintain the highest sensitivity for up to 2X as long compared to existing SCIEX technology, particularly when running complex matrices.

     

DJet+ assembly is fully removable, allowing front-end serviceability so customers can maximize the uptime of their systems.

     

At 800 MRM per second, the SCIEX 7500+ system is the fastest SCIEX Triple Quad to date. This increases the scope for large quantitation panels that need to incorporate new compounds of interest, improving the overall productivity of the lab.

     

Supported by new functionality in SCIEX OS that allows users to track instrument performance and automate decision making, reducing the potential for failed batches and repeat measurements.

     

Compatibility with dry roughing pumps can reduce electricity consumption by 24% relative to oil-sealed pumps.

“Over the years, we have worked with experts in the field and innovated various breakthrough quantitative solutions. We have seen demand increase for testing on more and more sample types at high sensitivity. The SCIEX 7500+ system meets these needs by ensuring the highest performance can be maintained for longer and across these increasingly complex matrices,” said Joe Fox, President at SCIEX.

Learn more about the SCIEX 7500+ system by visiting www.sciex.com/7500plus.

About SCIEX

SCIEX empowers our customers to solve the most impactful analytical challenges in quantitation and characterization. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field for over 50 years. ​

Since the launch of the first-ever commercially successful triple quadrupole in 1981, we continue to develop technologies and solutions that influence life-changing research and outcomes. That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust. ​

Advances in human wellness depend on the power of precise science.​

For more information, visit sciex.com. ​

Connect with us on LinkedIn, Facebook, X (Twitter) and Instagram.​

SCIEX is proud to be part of Danaher. ​

Danaher’s science and technology leadership puts SCIEX solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).

© 2024 DH Tech. Dev. Pte. Ltd. MKT- 31792.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240603002122/en/

CONTACT

Lulu VanZandt

Senior Manager, Brand, Public Relations and Social Media

lulu.vanzandt@sciex.com

M: +1 (508) 782-9484

同じカテゴリーの記事 

  • European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)
  • JCR Pharmaceuticals Highlights Innovative Gene Therapy Research at the 7th International Forum of Lysosomal Disorders
  • Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance
  • ベイジーン、アーロン・ローゼンバーグ氏を最高財務責任者に任命
  • ICH and CDISC Collaborate to Support the Maintenance and Governance Process for ICH M11 Controlled Terminology